Earlier research demonstrated that when AR-positive prostate cancer cells were treated with a proteolysis-targeting chimera (PROTAC) that degraded the ATPase subunits of the SWI/SNF chromatin remodeling complex (namely SMARCA2 and SMARCA4), it led to physical compaction of enhancer elements4. The gene discussed is SMARCA4; the disease is prostate carcinoma.